Elegant Science. Profound Improvement.

Chase intends to meaningfully improve the symptomatic treatment of Alzheimer’s disease, building on well-established science with an innovative patent-protected approach to greatly enhance the likelihood of success.

Alzheimer’s disease, already a worldwide crisis, is on the rise. In the United States alone a new Alzheimer’s patient is diagnosed each minute, over 5 million patients suffer, loved ones dedicate billions of unpaid caregiver hours, and the societal cost is hundreds of billions of dollars.

And yet, while enormous energy and investment has gone into the development of new Alzheimer’s solutions, the failure rate of R&D focused on Alzheimer’s is staggering, leaving patients and physicians with few treatment choices.

The one development approach proven successful and resulting in efficacious medicines is based on the “hypocholinergic hypothesis.” The brain communicates with itself through the release of neurotransmitters such as acetylcholine across trillions of synapses, the small gaps between neurons. Alzheimer’s disease progressively weakens acetylcholine neurotransmission and as acetylcholine communication decreases, human cognition becomes increasingly impaired along with much of what makes us who we are, including our memory, knowledge, judgment, reasoning, mood and language.

Today the standard-of-care treatment for Alzheimer’s disease is acetylcholinesterase inhibitors (AChEIs), drugs that have been proven to improve the amount and duration-of-action of acetylcholine in the brain. Unfortunately, current AChEIs are only modestly effective in improving cognition because side effects such as retching, diarrhea, nausea and vomiting limit their dosing to sub-effective levels.

Register for Updates from Chase Pharmaceuticals

Sign up to receive news about Chase Pharmaceuticals. All information will be kept confidential and secure.